Literature DB >> 30722947

Prevalence rate of social anxiety disorder in individuals with a psychotic disorder: A systematic review and meta-analysis.

Carla McEnery1, Michelle H Lim2, Hailey Tremain3, Ann Knowles4, Mario Alvarez-Jimenez5.   

Abstract

Social anxiety disorder (SAD) is characterised as an excessive fear of negative judgment from others and is considered one of the most disabling of the mental ill health conditions. Research findings indicate that it is also a significant issue for individuals diagnosed with a psychotic disorder, with prevalence rates of social anxiety ranging from 8% to 36%. This study was conducted to address the variance of the reported prevalence rates of comorbid SAD amongst individuals with a psychotic disorder diagnosis. Via a systematic review, we collated all available literature on the prevalence of SAD in individuals with a psychotic disorder, and evaluated the prevalence results via meta-analysis. We also synthesised all psychosocial outcomes attributed to SAD comorbidity and conducted a narrative review of the relevant findings. Across 25 studies providing data from 1980 to May 2018 and spanning 13 countries (N = 92,522), we found a pooled prevalence rate of 21% (16%-26%). In outpatient samples, (17 studies), the prevalence was 25% (19%-31%), statistically significantly higher (z = 5.12, p < .001) than that of the inpatient studies six studies, which was 9% (7%-12%). We also found that SAD comorbidity is associated with increased depression, poorer social function, poorer subjective quality of life, greater negative self-evaluation, and greater insight. The results from this systematic review and meta-analysis suggest that SAD is prevalent amongst individuals with a psychotic disorder. More consistent screening for SAD and the development of theoretically driven and empirically supported tailored treatments are recommended.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Prevalence; Psychosis; Schizophrenia; Social anxiety

Mesh:

Year:  2019        PMID: 30722947     DOI: 10.1016/j.schres.2019.01.045

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  6 in total

Review 1.  Revisiting Preclinical Observations of Several Histamine H3 Receptor Antagonists/Inverse Agonists in Cognitive Impairment, Anxiety, Depression, and Sleep-Wake Cycle Disorder.

Authors:  Mera Alhusaini; Nermin Eissa; Ali K Saad; Rami Beiram; Bassem Sadek
Journal:  Front Pharmacol       Date:  2022-06-01       Impact factor: 5.988

2.  Associations Of Personality Traits With The Capacity-Performance Discrepancy Of Functional Outcome In Patients With Schizophrenia.

Authors:  Takashi Uchino; Takahiro Nemoto; Taiju Yamaguchi; Naoyuki Katagiri; Naohisa Tsujino; Yoshitaka Murakami; Kuniaki Tanaka; Masafumi Mizuno
Journal:  Neuropsychiatr Dis Treat       Date:  2019-10-03       Impact factor: 2.570

3.  Disrupted Eye Gaze Perception as a Biobehavioral Marker of Social Dysfunction: An RDoC Investigation.

Authors:  Ivy F Tso; Carly A Lasagna; Kate D Fitzgerald; Costanza Colombi; Chandra Sripada; Scott J Peltier; Timothy D Johnson; Katharine N Thakkar
Journal:  J Psychiatr Brain Sci       Date:  2020-09-10

4.  Burden of schizophrenia among Japanese patients: a cross-sectional National Health and Wellness Survey.

Authors:  Kenji Baba; Wenjia Guo; Yirong Chen; Tadashi Nosaka; Tadafumi Kato
Journal:  BMC Psychiatry       Date:  2022-06-18       Impact factor: 4.144

5.  The interplay between psychopathological symptoms: transdiagnostic cross-lagged panel network model.

Authors:  UnYoung Chavez-Baldini; Karin Verweij; Derek de Beurs; Claudi Bockting; Anja Lok; Arjen L Sutterland; Geeske van Rooijen; Guido van Wingen; Damiaan Denys; Nienke Vulink; Dorien Nieman
Journal:  BJPsych Open       Date:  2022-06-27

6.  The Experience Among College Students with Social Anxiety Disorder in Social Situations: A Qualitative Study.

Authors:  Ya-Song Luan; Gao Zhan-Ling; Li Mi; Liu Ying; Bai Lan; Li Tong
Journal:  Neuropsychiatr Dis Treat       Date:  2022-08-15       Impact factor: 2.989

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.